Brief: Argenx: FDA Accepts Priority Review sBLA for Vyvgart in Seronegative gMG
13/01/2026 06:03
Jan 13 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR VYVGART IN ACHR-AB SERONEGATIVE GMG APPLICATION HAS BEEN GRANTED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 10, 2026 Source text: nGNE3qdF54 Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))